bupropion has been researched along with Asialia in 8 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with CBT + bupropion resulted in a better 6-month rate of smoking cessation compared to CBT+nortriptyline or CBT + placebo." | 9.12 | A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. ( Cesari, DH; Chatkin, JM; Fam, CF; Fritscher, CC; Haggsträm, FM; Sussenbach-Vaz, E, 2006) |
| "We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG)." | 9.12 | Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. ( Allen, J; Argo, T; Arndt, S; Black, DW; Coryell, WH; Forbush, KT; Perry, P; Shaw, MC, 2007) |
| "Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid to smoking cessation and has since been launched in many other countries." | 8.81 | Tolerability and safety of sustained-release bupropion in the management of smoking cessation. ( Aubin, HJ, 2002) |
| " Each drug, besides its therapeutic effect, creates the risk of adverse reactions which number and severity is not always accepted by the patient." | 5.39 | [Safety of nicotine addiction treatment]. ( Cieślewicz, A; Jabłecka, A; Korzeniowska, K, 2013) |
| "Treatment with CBT + bupropion resulted in a better 6-month rate of smoking cessation compared to CBT+nortriptyline or CBT + placebo." | 5.12 | A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. ( Cesari, DH; Chatkin, JM; Fam, CF; Fritscher, CC; Haggsträm, FM; Sussenbach-Vaz, E, 2006) |
| "We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG)." | 5.12 | Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. ( Allen, J; Argo, T; Arndt, S; Black, DW; Coryell, WH; Forbush, KT; Perry, P; Shaw, MC, 2007) |
| "Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid to smoking cessation and has since been launched in many other countries." | 4.81 | Tolerability and safety of sustained-release bupropion in the management of smoking cessation. ( Aubin, HJ, 2002) |
| "Bupropion was studied in four double-blind, placebo-controlled trials (N = 360) at dosages of 300-750 mg/day." | 2.65 | Methodologic approach to adverse events applied to bupropion clinical trials. ( Cato, AE; Cook, L; Heatherington, D; Starbuck, R, 1983) |
| " Each drug, besides its therapeutic effect, creates the risk of adverse reactions which number and severity is not always accepted by the patient." | 1.39 | [Safety of nicotine addiction treatment]. ( Cieślewicz, A; Jabłecka, A; Korzeniowska, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korzeniowska, K | 1 |
| Cieślewicz, A | 1 |
| Jabłecka, A | 1 |
| Aubin, HJ | 1 |
| Haggsträm, FM | 1 |
| Chatkin, JM | 1 |
| Sussenbach-Vaz, E | 1 |
| Cesari, DH | 1 |
| Fam, CF | 1 |
| Fritscher, CC | 1 |
| Black, DW | 1 |
| Arndt, S | 1 |
| Coryell, WH | 1 |
| Argo, T | 1 |
| Forbush, KT | 1 |
| Shaw, MC | 1 |
| Perry, P | 1 |
| Allen, J | 1 |
| Barrow, SY | 1 |
| Cato, AE | 1 |
| Cook, L | 1 |
| Starbuck, R | 1 |
| Heatherington, D | 1 |
| Hughes, S | 1 |
| Barnett, S | 1 |
| Sosnouski, P | 1 |
| Kirksey, DF | 1 |
| Levine, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bupropion Versus Placebo in the Treatment of Pathological Gambling[NCT00055393] | 80 participants (Actual) | Interventional | 2002-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for bupropion and Asialia
| Article | Year |
|---|---|
Tolerability and safety of sustained-release bupropion in the management of smoking cessation.
Topics: Bupropion; Clinical Trials as Topic; Consumer Product Safety; Delayed-Action Preparations; Dopamine | 2002 |
3 trials available for bupropion and Asialia
| Article | Year |
|---|---|
A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results.
Topics: Adrenergic Uptake Inhibitors; Bupropion; Counseling; Delayed-Action Preparations; Double-Blind Metho | 2006 |
Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Diagnostic and Statistical Manu | 2007 |
Methodologic approach to adverse events applied to bupropion clinical trials.
Topics: Akathisia, Drug-Induced; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Diso | 1983 |
4 other studies available for bupropion and Asialia
| Article | Year |
|---|---|
[Safety of nicotine addiction treatment].
Topics: Abdominal Pain; Adult; Alkaloids; Azocines; Benzazepines; Boredom; Bupropion; Female; Headache; Huma | 2013 |
Is your knowledge up-to-date?
Topics: Antidepressive Agents, Second-Generation; Bupropion; Humans; Male; Middle Aged; Smoking Cessation; X | 2008 |
A clinical trial of bupropion in the treatment of depressed outpatients.
Topics: Adult; Aged; Ambulatory Care; Bupropion; Cognition Disorders; Depression; Drug Evaluation; Drug Inte | 1984 |
Briefing paper--Zyban.
Topics: Bupropion; Dopamine Uptake Inhibitors; Humans; Smoking Cessation; Xerostomia | 2000 |